Cargando…

Rivaroxaban Monotherapy in Patients With Atrial Fibrillation and Coronary Stenting at Multiple Vessels or the Left Main Trunk: The AFIRE Trial Subanalysis

Detalles Bibliográficos
Autores principales:	Ishii, Mitsuru, Akao, Masaharu, Yasuda, Satoshi, Kaikita, Koichi, Ako, Junya, Matoba, Tetsuya, Nakamura, Masato, Miyauchi, Katsumi, Hagiwara, Nobuhisa, Kimura, Kazuo, Hirayama, Atsushi, Matsui, Kunihiko, Ogawa, Hisao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9673635/ https://www.ncbi.nlm.nih.gov/pubmed/36285792 http://dx.doi.org/10.1161/JAHA.122.027107

Ejemplares similares

Rivaroxaban Underdose for Atrial Fibrillation with Stable Coronary Disease: The AFIRE Trial Findings
por: Arashi, Hiroyuki, et al.
Publicado: (2022)

The impact of kidney function in patients on antithrombotic therapy: a post hoc subgroup analysis focusing on recurrent bleeding events from the AFIRE trial
por: Matsui, Kunihiko, et al.
Publicado: (2022)

Antithrombotic Therapy for Atrial Fibrillation and Coronary Artery Disease in Patients With Prior Atherothrombotic Disease: A Post Hoc Analysis of the AFIRE Trial
por: Matsuzawa, Yasushi, et al.
Publicado: (2021)

Rivaroxaban Monotherapy in Atrial Fibrillation and Stable Coronary Artery Disease Across Body Mass Index Categories
por: Ishii, Masanobu, et al.
Publicado: (2022)

Risk prediction score for clinical outcome in atrial fibrillation and stable coronary artery disease
por: Ishii, Masanobu, et al.
Publicado: (2023)

Rivaroxaban Treatment for Patients With Unprovoked or Provoked Venous Thromboembolism　― Subanalysis of the J’xactly Study ―
por: Hisatake, Shinji, et al.
Publicado: (2022)

Duration of Initial Intensive Rivaroxaban Therapy for Patients With Venous Thromboembolism　― Subanalysis of the J’xactly Study ―
por: Nakamura, Mashio, et al.
Publicado: (2023)

AFIR: A Dimensionless Potency Metric for Characterizing the Activity of Monoclonal Antibodies
por: Stein, AM, et al.
Publicado: (2017)

Study design of GENERAL (general practitioners and embolism prevention in NVAF patients treated with rivaroxaban: Real-life evidence): A multicenter prospective cohort study in primary care physicians to investigate the effectiveness and safety of rivaroxaban in Japanese patients with NVAF
por: Kusano, Kengo, et al.
Publicado: (2017)

Total adiponectin is associated with incident cardiovascular and renal events in treated hypertensive patients: subanalysis of the ATTEMPT-CVD randomized trial
por: Kim-Mitsuyama, Shokei, et al.
Publicado: (2019)

Oral Anticoagulant Use in Elderly Japanese Patients With Non-Valvular Atrial Fibrillation　― Subanalysis of the ANAFIE Registry ―
por: Akao, Masaharu, et al.
Publicado: (2020)

Impact of anemia on the clinical outcomes in elderly patients with atrial fibrillation receiving apixaban: J-ELD AF registry subanalysis
por: Tanaka, Nobuaki, et al.
Publicado: (2022)

Clinical Outcomes of Very Elderly Patients With Atrial Fibrillation Receiving On‐label Doses of Apixaban: J‐ELD AF Registry Subanalysis
por: Okada, Masato, et al.
Publicado: (2021)

Rivaroxaban Monotherapy in Patients with Pulmonary Embolism: Off-Label vs. Labeled Therapy
por: Di Micco, Pierpaolo, et al.
Publicado: (2022)

Current status of proton pump inhibitor use in Japanese elderly patients with non-valvular atrial fibrillation: A subanalysis of the ANAFIE Registry
por: Mizokami, Yuji, et al.
Publicado: (2020)

Polyunsaturated Fatty Acid Impact on Clinical Outcomes in Acute Coronary Syndrome Patients With Dyslipidemia: Subanalysis of HIJ‐PROPER
por: Arashi, Hiroyuki, et al.
Publicado: (2019)

Magnetic properties of Fe(3)O(4) antidot arrays synthesized by AFIR: atomic layer deposition, focused ion beam and thermal reduction
por: Palma, Juan L, et al.
Publicado: (2018)

Efficacy and Safety of Edoxaban 15 mg According to Renal Function in Very Elderly Patients With Atrial Fibrillation: A Subanalysis of the ELDERCARE-AF Trial
por: Yoshida, Tetsuro, et al.
Publicado: (2022)

Rivaroxaban Monotherapy for Atrial Fibrillation and Coronary Artery Disease in Underweight/Obese Patients: Evidence Is Needed
por: Zhou, Dao, et al.
Publicado: (2022)

Effect of 15-mg Edoxaban on Clinical Outcomes in 3 Age Strata in Older Patients With Atrial Fibrillation: A Prespecified Subanalysis of the ELDERCARE–AF Randomized Clinical Trial
por: Kuroda, Masaru, et al.
Publicado: (2022)

Ticagrelor Monotherapy After 3-Month Dual Antiplatelet Therapy in Acute Coronary Syndrome by High Bleeding Risk: The Subanalysis From the TICO Trial
por: Lee, Yong-Joon, et al.
Publicado: (2021)

Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism – the J-EINSTEIN DVT and PE program
por: Yamada, Norikazu, et al.
Publicado: (2015)

Utility of handgrip stress test in patients with functional mitral regurgitation and exertional dyspnoea
por: Hamatani, Yasuhiro, et al.
Publicado: (2020)

Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study
por: Kang, Yoon-Koo, et al.
Publicado: (2021)

Erratum to: ‘Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism – the J-EINSTEIN DVT and PE program’
por: Yamada, Norikazu, et al.
Publicado: (2016)

Cardioprotective Effects of Rivaroxaban on Cardiac Remodeling After Experimental Myocardial Infarction in Mice
por: Nakanishi, Nobuhiro, et al.
Publicado: (2020)

Cardioprotective Effects of Rivaroxaban on Cardiac Remodeling After Experimental Myocardial Infarction in Mice
por: Nakanishi, Nobuhiro, et al.
Publicado: (2020)

Rate Pressure Products Affect the Relationship between the Fractional Flow Reserve and Instantaneous Wave-Free Ratio
por: Ebihara, Suguru, et al.
Publicado: (2020)

Features of trunk muscle wasting during acute care and physical function recovery with aortic disease
por: Yamashita, Masashi, et al.
Publicado: (2022)

Prognostication of Patients with Pulmonary Thromboembolism with and without Residual Deep Vein Thrombosis: A Subanalysis of the J’xactly Study
por: Yamada, Norikazu, et al.
Publicado: (2023)

DFT and AFIR study on the copper(i)-catalyzed mechanism of 5-enamine-trisubstituted-1,2,3-triazole synthesis via C–N cross-coupling and the origin of ring-opening of 2H-azirines
por: Yu, Fan, et al.
Publicado: (2021)

Dual Antiplatelet Therapy Using Cilostazol With Aspirin or Clopidogrel: Subanalysis of the CSPS.com Trial
por: Hoshino, Haruhiko, et al.
Publicado: (2021)

Blood Oxygen, Sleep Disordered Breathing, and Respiratory Instability in Patients With Chronic Heart Failure　― PROST Subanalysis ―
por: Tobushi, Tomoyuki, et al.
Publicado: (2019)

Differential Effect of Low-Dose Aspirin for Primary Prevention of Atherosclerotic Events in Diabetes Management: A subanalysis of the JPAD trial
por: Okada, Sadanori, et al.
Publicado: (2011)

Biochemical Markers Reflecting Thyroid Function in Athyreotic Patients on Levothyroxine Monotherapy
por: Ito, Mitsuru, et al.
Publicado: (2017)

Hepatomesenteric Trunk Dissection Complicated with Acalculous Cholecystitis
por: Yamaguchi, Satoshi, et al.
Publicado: (2022)

Rivaroxaban in atrial fibrillation
por: Giorgi, Mariano A, et al.
Publicado: (2012)

Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment
por: Oddone, Francesco, et al.
Publicado: (2022)

Primary and secondary prevention of stroke and systemic embolism with rivaroxaban in patients with non-valvular atrial fibrillation: Sub-analysis of the EXPAND Study
por: Uchiyama, Shinichiro, et al.
Publicado: (2018)

Low-Dose Aspirin Therapy in Patients With Type 2 Diabetes and Reduced Glomerular Filtration Rate: Subanalysis from the JPAD trial
por: Saito, Yoshihiko, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_ag1er7t1qbnfuhi6ff6d3fnujm